NYXH Nyxoah
Company Analysis
Latest News
Cantor Fitzgerald Reiterates Overweight Rating Following Positive Trial Results
Cantor Fitzgerald reiterated its Overweight rating and $6.00 price target for Nyxoah SA on September 4, 2026. The affirmation follows the company's...
🔴 Nyxoah is trading 5.1% down today with no new company-specific catalyst identified
Nyxoah is trading at $1.67 (-5.11%) on September 4, 2026; no new company-specific catalyst directly explaining the decline was identified. - It closed at...
🟢 Nyxoah is trading 18.87% up today after ACCCESS U.S. pivotal study meets primary endpoints
Nyxoah is trading at $1.79, +18.87% after its September 2, 2026 ACCCESS U.S. pivotal study met primary safety and efficacy endpoints. - At 12 months, AHI and...
🟢 Nyxoah is trading 17.85% up in pre-market after ACCCESS study meets safety and efficacy endpoints
Nyxoah is trading 17.85% up at $1.78 after its September 2, 2026 announcement that the ACCCESS U.S. pivotal study met primary safety and efficacy endpoints. -...
Nyxoah's Sleep Apnea Device Aces a Key Trial — But Can a $170 Million Company Turn Clinical Data Into Commercial Traction?
Shares of Nyxoah jumped 11.3% to $1.68 after the Belgian medtech firm reported that its U.S. pivotal trial for a hard-to-treat subset of sleep apnea patients...
🟢 Nyxoah is trading 11.26% up in after-hours trading after ACCCESS study met primary endpoints
Nyxoah is trading $1.68 (+11.26%) after its ACCCESS U.S. pivotal study met primary efficacy and safety endpoints. - Nyxoah announced the results on September...
🟢 Nyxoah is trading 6.7% up in after-hours trading with no confirmed catalyst
Nyxoah is trading 6.66% up now at $1.59 in after-hours trading, versus a $1.49 close on September 1, 2026, with the catalyst unconfirmed. - Investor relations...
🟢 Nyxoah is trading 5% up in pre-market with no clear company-specific catalyst
Nyxoah is trading 5.13% up at $1.64 in pre-market on September 1, 2026, with no clear company-specific catalyst identified. - Investor-relations page lists...
🟢 Nyxoah is trading 5.7% up in pre-market with no fresh company-specific catalyst identified
Nyxoah is trading $1.67 (+5.70%) up now after no fresh company-specific catalyst was identified for August 14, 2026. • The latest identifiable company update...
🟢 Nyxoah is trading 5.78% up today as immediate catalyst remains unclear
Nyxoah is trading at $1.55 (+5.78%) as recent momentum follows its August 5 earnings report, though the immediate catalyst remains unclear. - No new...
Nyxoah downgraded to sell, following wider-than-expected quarterly loss
Wall Street Zen downgraded Nyxoah (NASDAQ: NYXH) from hold to sell on August 9, 2026. The rating change follows the company’s second-quarter earnings report...
Nyxoah's Sleep Apnea Device Is Gaining Traction in the U.S. — But Can a $1.41 Stock Grow Into Its Ambitions?
Shares of Nyxoah jumped 7.6% to $1.41 as investors continued to digest second-quarter results showing the Belgian medtech company's implantable...
🟢 Nyxoah is trading 8.78% up today after reiterated 2026 revenue guidance
Nyxoah is trading 8.78% up now at $1.43 as investors continue assessing its August 5 earnings report and August 6 call. - Q2 revenue reached €7.7 million;...
🟢 Nyxoah is trading 7.63% up in pre-market after strong Q2 results
Nyxoah is trading 7.63% up in pre-market at $1.41 after investors continued to digest strong second-quarter results released on August 5. - Global revenue...
🔴 Nyxoah is trading 5.7% down today on continued heavy losses despite strong Q2 growth
Nyxoah is trading 5.7% down at $1.33 after its August 5, 2026 earnings release delivered strong revenue growth but continued heavy losses. - Q2 revenue...
🔴 Nyxoah is trading 5.7% down today after Q2 earnings release
Nyxoah is trading 5.7% down at $1.33 in pre-market following its second-quarter earnings release. • The company reported strong revenue growth driven by the...
🟢 Nyxoah is trading 5.5% up today after Q2 revenue beat and reiterated guidance
Nyxoah is trading at $1.49 (+5.48%) after hours after reporting second-quarter 2026 revenue that significantly exceeded analyst estimates. • Quarterly revenue...
Nyxoah's second quarter revenue of €7.7 million beats estimates, driven by strong U.S. launch momentum.
Nyxoah reported second quarter global net revenue of €7.7 million, a significant increase from €1.3 million in the prior-year period, driven by the ongoing...
Nyxoah Q2 2026 Earnings Preview: What Analysts Expect on August 05, 2026
Nyxoah is expected to report a Q2 2026 loss of $0.47 per share on consensus revenue of $3.85 million, with the current $13.40 stock price trading significantly...
🔴 Nyxoah is trading 5.4% down today with no clear company-specific catalyst
Nyxoah is trading 5.4% down at $1.39 today amid a quiet news backdrop, with no fresh company-specific developments or major announcements hitting the tape. •...